{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:14:29Z","timestamp":1784139269483,"version":"3.55.0"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To report 5\u2010year outcomes from the STRATified CANcer Surveillance (STRATCANS) programme based on progression risks using National Institute for Health and Clinical Excellence (NICE) Cambridge Prognostic Group (CPG) at diagnosis, prostate specific antigen density and magnetic resonance imaging (MRI) visibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Men with CPG1 and CPG2 disease selecting active surveillance (AS) were included into STRATCANS and allocated to one of three increasing follow\u2010up intensities. Outcome measures were: (i) treatment for CPG\u22653 progression (main outcome), (ii) any treatment, (iii) conversion to watchful waiting (WW), (iv) patient self\u2010attrition, and (v) mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 297 men (median age 66.0\u2009years) were reviewed. The median (interquartile range, mean) follow\u2010up for men still on AS was 4.9\u2009(2.7\u20137.6, 5.3)\u2009years. In the cohort, 38.0% were CPG2 and 25.0% Grade Group (GG) 2 at AS entry. Overall, 214\/297 (72.1%) remained treatment free: 158 (53.1%) were still on AS, 17 (5.7%) died of other causes, and 39 (13.1%) progressed to WW\/discharge. Only 10 (3.4%) left AS from anxiety. There were no cancer deaths or metastatic events. In all, 80 men (26.9%) converted to treatment due to biopsy\/MRI progression but only 35 (11.7%) of these reached CPG\u22653 disease. Treatment for CPG\u22653 occurred in 7.6% of CPG1 and 18.5% of CPG2 disease and 9.9% of GG1 and 17.5% of GG2 disease. By STRATCANS tier, treatment for CPG\u22653 disease was 4.7% in STRATCANS 1, 12.9% in STRATCANS 2, and 27.4% in STRATCANS 3 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). STRATCANS had an area under the curve (AUC) of 0.74 for predicting CPG\u22653 progression out\u2010performing stratification by GG (AUC 0.64), CPG (0.69) and Likert score (0.51) alone or a combination of MRI visibility and GG (0.64). Longitudinal data have allowed further refinement of the STRATCANS schedule.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The STRATCANS 5\u2010year outcomes demonstrate that a simple risk stratified surveillance using a prognostically meaningful endpoint is safe, durable, has low treatment rates, high patient compliance and appropriately tailors monitoring based on risks of progression. A website and implementation toolkit are now available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16666","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:20:52Z","timestamp":1738203652000},"page":"851-859","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The 5\u2010year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer"],"prefix":"10.1111","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4722-4207","authenticated-orcid":false,"given":"Vincent J.","family":"Gnanapragasam","sequence":"first","affiliation":[{"name":"Department of Surgery University of Cambridge  Cambridge UK"},{"name":"Cambridge Prostate Cancer and Clinical Trials Group  Cambridge UK"},{"name":"Urology Cambridge University Hospitals  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Keates","sequence":"additional","affiliation":[{"name":"Cambridge Prostate Cancer and Clinical Trials Group  Cambridge UK"},{"name":"Urology Cambridge University Hospitals  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artitaya","family":"Lophatananon","sequence":"additional","affiliation":[{"name":"Division of Population Health, Health Services Research and Primary Care Centre University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineetha","family":"Thankapannair","sequence":"additional","affiliation":[{"name":"Urology Cambridge University Hospitals  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.11.024"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.29760"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-015-0049-y"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14106"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02641-7"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.10.025"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/CU9.0000000000000203"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-023-01177-2"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.07.006"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2017.01.13"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.313"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1019-5"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14800"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.12.013"},{"key":"e_1_2_12_16_1","first-page":"S82","article-title":"Application of the stratcans criteria to the music as cohort: a step towards risk stratified active surveillance","volume":"42","author":"Wang M","year":"2024","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"e_1_2_12_17_1","unstructured":"Available at:https:\/\/www.nice.org.uk\/guidance\/NG131. Accessed November 2024"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07336-0"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.035"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14707"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2020.151045"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10863-9"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16214"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.05.001"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210321"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24556"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"key":"e_1_2_12_29_1","unstructured":"Available at:https:\/\/www.isrctn.com\/ISRCTN11447662. Accessed November 2024"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391\u2010024\u201000888\u2010y"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295994"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126266"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10869-3"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-024-01219-3"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/UPJ.0000000000000679"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003461"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010216"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040629"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00659-w"},{"key":"e_1_2_12_40_1","unstructured":"Available at:https:\/\/www.stratcans.com. Accessed November 2024"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:55:48Z","timestamp":1761756948000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/bju.16666"],"URL":"https:\/\/doi.org\/10.1111\/bju.16666","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"2025-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}